Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Minute Insight: J&J’s Drug Eluting Lens Blurs A Line While Helping Patients See Clearly

Executive Summary

Theravision with ketotifen has received FDA approval.

You may also be interested in...



Exec Chat: J&J’s Menziuso Looks To Extend Vision Care To Underserved Places And People

Johnson & Johnson Vision recently named Peter Menziuso as company group chairman. In a Q&A with Medtech Insight, he his vision for the company and how the company is in a strong position bring vision care to more people.

News We’re Watching – US FDA Updates, Digital Therapeutics Legislation, AI Endoscopies, Monkeypox EUA, And New AdvaMed Chair

The US Food and Drug Administration recently issued updates regarding improvements to its online submissions portal, enhancements to its electronic medical device reporting system, pediatric X-ray guidance, expanded indications for a popular breathing device, and mammogram guidelines; and more news we’re watching.

Is Time Nearly Up For Pear? The PDT Company Could Be Bargain For Acquirer

Despite earlier efforts to restructure, the company is still struggling to meet its revenue targets, and issued a statement suggesting that further measures, including liquidation, may be necessary.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT145141

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel